Immunomagnetic CD45 depletion does not improve cytokeratin 20 RT-PCR in colorectal cancer

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 3, 2007, Pages 351-356

  Ausch, Christoph ^a,d   Dandachi, Nadia ^b   Buxhofer Ausch, Veronika ^a   Balic, Marija ^b   Huber, Klaus ^a   Bauernhofer, Thomas ^b   Ogris, Emil ^a   Hinterberger, Wolfgang ^a   Braun, Stephan ^c   Schiessel, Rudolf ^a  

^a DANUBE HOSPITAL   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

CD45 depletion; Colorectal cancer; Cytokeratin 20 reverse transcriptase PCR; Ficoll density gradient separation

Indexed keywords

CD45 ANTIGEN; CYTOKERATIN 20; FICOLL; MESSENGER RNA;

BLOOD SAMPLING; BONE MARROW CELL; CANCER PATIENT; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; GENETIC TRANSCRIPTION; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; MEDICAL INSTRUMENTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

ANTIGENS, CD; ANTIGENS, CD45; BONE MARROW CELLS; CENTRIFUGATION, DENSITY GRADIENT; COLORECTAL NEOPLASMS; HUMANS; IMMUNOMAGNETIC SEPARATION; KERATIN-20; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33947586741     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2007.059     Document Type: Conference Paper

References (39)

1. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000;342:525-33.
2. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353:793-802.
3. Feezor RJ, Copeland EM III, Hochwald SN. Significance of micrometastases in colorectal cancer. Ann Surg Oncol 2002;9:944-53.
4. Lugo TG, Braun S, Cote RJ, Pantel K, Rusch V. Detection and measurement of occult disease for the prognosis of solid tumors. J Clin Oncol 2003;21:2609-15.
5. Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 2005;65:1141-5.
6. Muller HM, Fiegl H, Widschwendter A, Widschwendter M. Prognostic DNA methylation marker in serum of cancer patients. Ann NY Acad Sci 2004;1022:44-9.
7. Widschwendter A, Gattringer C, Ivarsson L, Fiegl H, Schneitter A, Ramoni A, et al. Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors. Clin Cancer Res 2004;10:3396-400.
8. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.
9. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420-30.
10. Vlems FA, Diepstra JH, Cornelissen IM, Ruers TJ, Ligtenberg MJ, Punt CJ, et al. Limitations of cytokeratin 20 RT-PCR to detect disseminated tumour cells in blood and bone marrow of patients with colorectal cancer: expression in controls and downregulation in tumour tissue. Mol Pathol 2002;55:156-63.
11. Bustin SA, Gyselman VG, Williams NS, Dorudi S. Detection of cytokeratins 19/20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients. Br J Cancer 1999;79:1813-20.
12. Champelovier P, Mongelard F, Seigneurin D. CK20 gene expression: technical limits for the detection of circulating tumor cells. Anticancer Res 1999;19:2073-8.
13. Funaki NO, Tanaka J, Ohshio G, Onodera H, Maetani S, Imamura M. Cytokeratin 20 mRNA in peripheral venous blood of colorectal carcinoma patients. Br J Cancer 1998;77:1327-32.
14. Jung R, Petersen K, Kruger W, Wolf M, Wagener C, Zander A, et al. Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes. Br J Cancer 1999;81:870-3.
15. Soeth E, Roder C, Juhl H, Kruger U, Kremer B, Kalthoff H. The detection of disseminated tumor cells in bone marrow from colorectal-cancer patients by a cytokeratin-20-specific nested reverse-transcriptase-polymerase-chain reaction is related to the stage of disease. Int J Cancer 1996;69:278-82.
16. Guo J, Xiao B, Jin Z, Qin L,Chen J, Chen H, et al. Detection of cytokeratin 20 mRNA in peripheral blood of patients with colorectal cancer by immunomagnetic bead enrichment and real-time reverse transcriptase-polymerase chain reaction. J Gastroenterol Hepatol 2005;20:1279-84.
17. Sabile A, Louha M, Bonte E, Poussin K, Vona G, Mejean A, et al. Efficiency of Ber-EP4 antibody for isolating circulating epithelial tumor cells before RT-PCR detection. Am J Clin Pathol 1999;112:171-8.
18. Weitz J, Kienle P, Lacroix J, Willeke F, Benner A, Lehnert T, et al. Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res 1998;4:343-8.
19. Guo J, Xiao B, Zhang X, Jin Z, Chen J, Qin L, et al. Combined use of positive and negative immunomagnetic isolation followed by real-time RT-PCR for detection of the circulating tumor cells in patients with colorectal cancers. J Mol Med 2004;82:768-74.
20. International Union Against Cancer. TNM classification of malignant tumors, 5th ed. New York: Springer, 1997.
21. Dandachi N, Balic M, Stanzer S, Halm M, Resel M, Hinterleitner TA, et al. Critical evaluation of real-time reverse transcriptase-polymerase chain reaction for the quantitative detection of cytokeratin 20 mRNA in colorectal cancer patients. J Mol Diagn 2005;7:631-7.
22. Witzig TE, Bossy B, Kimlinger T, Roche PC, Ingle JN, Grant C, et al. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 2002;8:1085-91.
23. Gottschalk J, Jautzke G, Zimmer C, Cervos-Navarro J. HEA 125 and Ber EP4: two monoclonal anti-epithelial, non-cytokeratin antibodies distinguishing metastatic carcinomas from glial tumors. Clin Neuropathol 1993;12:68-72.
24. Moldenhauer G, Momburg F, Moller P, Schwartz R, Hammerling GJ. Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. Br J Cancer 1987;56:714-21.
25. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004;35:122-8.
26. Pantel K, Otte M. Occult micrometastasis: enrichment, identification and characterization of single disseminated tumour cells. Semin Cancer Biol 2001;11:327-37.
27. Koch M, Kienle P, Hinz U, Antolovic D, Schmidt J, Herfarth C, et al. Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases. Ann Surg 2005;241:199-205.
28. Schuster R, Max N, Mann B, Heufelder K, Thilo F, Grone J, et al. Quantitative real-time RT-PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers. Int J Cancer 2004;108:219-27.
29. Thorban S, Rosenberg R, Maak M, Friederichs J, Gertler R, Siewert JR. Impact of disseminated tumor cells in gastrointestinal cancer. Expert Rev Mol Diagn 2006;6:333-43.
30. Burchill SA, Lewis IJ, Selby P. Improved methods using the reverse transcriptase polymerase chain reaction to detect tumour cells. Br J Cancer 1999;79:971-7.
31. Ladanyi A, Soong R, Tabiti K, Molnar B, Tulassay Z. Quantitative reverse transcription-PCR comparison of tumor cell enrichment methods. Clin Chem 2001;47:1860-3.
32. Vlems F, Soong R, Diepstra H, Punt C, Wobbes T, Tabiti K, et al. Effect of blood sample handling and reverse transcriptase-polymerase chain reaction assay sensitivity on detection of CK20 expression in healthy donor blood. Diagn Mol Pathol 2002;11:90-7.
33. Vlems FA, Ladanyi A, Gertler R, Rosenberg R, Diepstra JH, Roder C, et al. Reliability of quantitative reverse-transcriptase-PCR-based detection of tumour cells in the blood between different laboratories using a standardised protocol. Eur J Cancer 2003;39:388-96.
34. Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G. Prognostic significance of micrometastatic tumor cells in the bone marrow of colorectal cancer patients. Lancet 1992;340:685-8.
35. O'Connor OJ, Cahill RA, Kirwan WO, Redmond HP. The impact of bone marrow micrometastases on metastatic disease free survival in patients with colorectal carcinoma. Colorectal Dis 2005;7:406-9.
36. Woelfle U, Breit E, Zafrakas K, Otte M, Schubert F, Muller V, et al. Bi-specific immunomagnetic enrichment of micrometastatic tumour cell clusters from bone marrow of cancer patients. J Immunol Methods 2005;300:136-45.
37. Naume B, Borgen E, Nesland JM, Beiske K, Gilen E, Renolen A, et al. Increased sensitivity for detection of micrometastases in bone-marrow/ peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation. Int J Cancer 1998;78:556-60.
38. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer 2005;5:744-9.
39. Hernandez BY, Frierson HF, Moskaluk CA, Li YJ, Clegg L, Cote TR, et al. CK20 and CK7 protein expression in colorectal cancer: demonstration of the utility of a population-based tissue microarray. Hum Pathol 2005;36:275-81.